Transfusion medicine

Audra Taylor joins executive team for Blood Operations at South Texas Blood & Tissue

Retrieved on: 
Tuesday, November 29, 2022
Marketing, SBB, Chemistry, BioBridge Global, Blood, Cancer, Tissue, Hospital, Department of Defense Serum Repository, Degenerative disease, Patient, Regenerative medicine, Brother, United States Air Force, Information management, Transfusion medicine, Research, AABB, Defense Health Agency, Resuscitation, Division, STB, Plasma, FDA, Management, Pharmaceutical industry, Vaccine, United States Navy, United States Army, Defense

San Antonio, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioBridge Global and South Texas Blood & Tissue announced today that Audra Taylor, SBB, is joining the organization as Executive Director for Blood Operations.

Key Points: 
  • San Antonio, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioBridge Global and South Texas Blood & Tissue announced today that Audra Taylor, SBB, is joining the organization as Executive Director for Blood Operations.
  • She will report directly to Adrienne B. Mendoza, Chief Operating Officer, South Texas Blood & Tissue.
  • About South Texas Blood & Tissue: South Texas Blood & Tissue (STB&T) is a nonprofit community blood center that provides blood, plasma, platelets and other blood components to 100 hospitals in 48 South Texas counties.
  • STB&T has nine donor centers in South Texas and conducts hundreds of mobile blood drives each year.

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients

Retrieved on: 
Monday, November 28, 2022
Health, Fitness & Nutrition, General Health, Pharmaceutical, Cardiology, Biotechnology, Marketing, CSL, Degenerative disease, Heart, Dizziness, Anemia, Diagnosis, Conditional sentence, Multimedia, Systematic review, Iron deficiency, Dialysis, Risk, NHC, Pica, Patient, PBM, Life, Iron, Clay, ASX, Face, Nutritional anemia, Fatigue, URL, World Health Organization, Australian Longitudinal Study on Women's Health, Disease, Common, Transfusion medicine, National Medical Products Administration, Veni, vidi, vici, BMC, NRDL, Collection, PLOS, Fresenius Medical Care, B, Woman, NMPA, Infection, Safety, Nephrology, Fresenius (company), Pharmaceutical industry, Health insurance, Dietary supplement, Hospital, Silviculture

View the full release here: https://www.businesswire.com/news/home/20221127005020/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
    CSL Vifor and Fresenius Kabi today announced that Chinas National Medical Products Administration (NMPA) has approved Ferinject, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly.
  • We are thrilled about the marketing authorization of Ferinject, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia, said Herv Gisserot, General Manager of CSL Vifor.
  • There is a high unmet need in China, which has the worlds largest iron deficiency population, and we are confident that Ferinject can make a meaningful difference in the treatment of these patients.
  • This open label, randomized multicenter study showed that Ferinject is an effective and well-tolerated alternative to iron sucrose for the treatment of iron deficiency anemia that can provide an improved hemoglobin response and correction of iron deficiency in Chinese patients.

invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Thomas Jefferson National Accelerator Facility, IO, Immunity, Escape Room, Convention center, Poster, Medical University of Vienna, Immunotherapy, Cancer, Department, Gesellschaft mit beschränkter Haftung, Serology, MTD, Glioblastoma, Boston Convention and Exhibition Center, TILS, Alveolar soft part sarcoma, Safety, Gene expression, CMSO, Sirna, SITC, Disease, Neoplasm, Clinical trial, Cell, Liver, Biotechnology, Medical school, Patient, Immune system, Peritoneum, Index (publishing), Hematological Cancer Research Investment and Education Act, Society, Transfusion medicine, Vaccine, Pharmaceutical industry, Medical imaging, Epic

Following tumor resection and 11 lines of prior systemic therapy, the patient was enrolled in the ongoing Phase 1b trial presenting with progressive disease.

Key Points: 
  • Following tumor resection and 11 lines of prior systemic therapy, the patient was enrolled in the ongoing Phase 1b trial presenting with progressive disease.
  • Treatment with APN401 was well tolerated and the patient presented with stable disease for 27 weeks, suggesting immunological anti-tumor activity resulting from treatment with APN401.
  • This supports the potency of APN401 and its potential as an effective therapeutic for malignancies, which is being further investigated in the ongoing clinical trial.
  • APN401 is currently being evaluated in a Phase 1b clinical trial in patients with advanced solid tumors.

HEMANEXT ANNOUNCES CLOSE OF SERIES B EQUITY FUNDING ROUND

Retrieved on: 
Monday, November 7, 2022
O2, Company, LR, Research, Exercise, CO2, Red blood cell, Merck, Board, Biotechnology, RBC, White blood cell, FDA, Safety, Ness, University of Cape Town, Johns Hopkins University, National, University, Division, CEO, Collection, UCB, Drug development, Board of directors, Transfusion medicine, Technology, Patient, Schering-Plough, University of Cambridge, Management, Pharmaceutical industry, Medical device, Nordic, Director, Medicine

LEXINGTON, Mass., Nov. 7, 2022 /PRNewswire/ -- Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced the successful first close of its Series B fundraising round. Taken together with the exercise of outstanding warrants, this close brings an additional $18 million of equity capital from noted global private investors with deep finance and healthcare expertise. To date, the company has raised approximately $130mm (inclusive of $8mm in grant funding from the National Institutes of Health).

Key Points: 
  • LEXINGTON, Mass., Nov. 7, 2022 /PRNewswire/ -- Hemanext Inc ., a leading innovator in blood processing, storage, and transfusion technology, today announcedthe successful firstclose of its Series B fundraising round.
  • Taken together with the exercise of outstanding warrants, this close bringsan additional $18 millionof equity capitalfromnoted globalprivate investorswithdeepfinance and healthcare expertise.
  • To date, the company has raised approximately $130mm (inclusive of $8mm in grant funding from the National Institutes of Health).
  • The Companywill be keepingthe current Series B available to investors for thenext few weeks.Hemanextexpects to begin a Series C roundwithinstitutional investorsin 2023.

Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Lymphatic system, Washington University in St. Louis, Society, DLBCL, Washington University School of Medicine, Knowledge, B-cell lymphoma, Hodgkin lymphoma, Macrophage, Multiple myeloma, Warsaw Stock Exchange, Growth, Merck, GLOBE, FLT3, ASH, RVU, Germinal center B-cell like diffuse large B-cell lymphoma, Publication, Phenotype, Safety, MDS, Drug resistance, Gene expression, Pharmacology, Transfusion medicine, Exposition, Plasma, MM, Institute, PIM, Carcinogenesis, Acute myeloid leukemia, Therapy, Myelodysplastic syndrome, Transplant, AML, Cognition and Neuroergonomics (CaN) Collaborative Technology Alliance, Cellular, Pharmaceutical industry, Medicinal plants, Patient, Hematology, MD

As of the cut-off date of July 25, 2022, 17 patients have been treated with RVU120.

Key Points: 
  • As of the cut-off date of July 25, 2022, 17 patients have been treated with RVU120.
  • Additionally, the on-target activity of RVU120 was evaluated in AML and HR-MDS patient samples by measuring changes in pSTAT5 levels.
  • Ryvu licensee, Menarini Group, and academic collaborators will present data on SEL24(MEN1703), a first-in-class, oral, dual type I PIM/FLT3 inhibitor.
  • We are also proud that our partner Menarini will showcase multiple preclinical data on SEL24 showing potential efficacy across multiple blood cancer models.

Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1

Retrieved on: 
Thursday, November 3, 2022
NASDAQ, Awareness, ADR Institute of Alberta, Regulation of tobacco by the U.S. Food and Drug Administration, Solution, FDA, Sale, Risk, MCE, CEO, Legislation, AAT, Population, Louise Sandhaus, COPD, GRF, Food, Industry, Pharmacy, Asthma, CDC, Diagnosis, EUR, Physician, Patient, Quality of life, Respiratory disease, Chronic obstructive pulmonary disease, Center, Health, Plasma, Home, Safety, S.A, Degenerative disease, Neurology, Lung, Hematology, Infection, Hospital, Liver disease, Transfusion medicine, Dietary supplement, Poultry, Pharmaceutical industry, Medical device, Grifols

The service, also known as AlphaID At Home, is the company's first FDA clearance for direct-to-consumer use.

Key Points: 
  • The service, also known as AlphaID At Home, is the company's first FDA clearance for direct-to-consumer use.
  • Alpha-1 is the most common risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases that includes emphysema and chronic bronchitis.
  • To use the safe saliva collection kit, individuals simply collect their sample and send it to a certified lab for processing.
  • Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

Cerus Corporation Announces Health Canada Approval for INTERCEPT Blood System for Platelets with Seven-Day Storage

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Medical Devices, Hospitals, Health, Medical Supplies, Cryoprecipitate, CERS, Plasma, Health, Time, Hospital, Bleeding, Blood, Nasdaq, CE, Platelet, Collection, Adoption, Health Canada, B cell, Transfusion medicine, Factor, FDA, CBS, Patient, Corporation, Pharmaceutical industry, Medical device, Blood product, Society of Spanish Researchers in the United Kingdom (SRUK/CERU), Canadian Blood Services

Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.
  • We look forward to working with Canadian Blood Services to realize these benefits for patients in Canada, Ms. Moore concluded.
  • The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Secure Transfusion Solutions Presents Data Demonstrating Feasibility and Safety of its Novel Compensated Blood Donation Model

Retrieved on: 
Monday, October 17, 2022
Quality of life, Trust, Infection, Female, Transfusion medicine, Risk, Bleeding, Surge (drink), Holiday, Hope, World Blood Donor Day, Motivation, Solution, IQR, Patient, Hospital, Annual general meeting, Collection, Cancer, AABB, Medical Affairs Bureau, Industry, Association, Abstract (summary), Social media, Safety, GLOBE, Ageing, Altruism, THBC, Male, STS, Medical device, Pharmaceutical industry, Blood product, Vassallo, Blood

Our data demonstrate the effectiveness of our model to recruit and retain younger platelet donors, both male and female.

Key Points: 
  • Our data demonstrate the effectiveness of our model to recruit and retain younger platelet donors, both male and female.
  • Our initial experience operating Trusting Heart Blood Center in Edina, Minnesota provides evidence of a solution towards a reliable and sustainable platelet supply.
  • Secure Transfusion Solutions (STS) is a life sciences company pioneering innovative methods to overcome the nations growing blood and platelet shortage.
  • By partnering with STS, hospital systems increase confidence in the sourcing of blood components, better preparing them to meet evolving patient transfusion needs.

QuidelOrtho Reports Preliminary Revenue Results for Third Quarter 2022

Retrieved on: 
Wednesday, October 12, 2022
Medical Supplies, Health, Infectious Diseases, COVID-19, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Interest, Transfusion medicine, Government, Webcast, Conference, Commission, Ortho Clinical Diagnostics, NASDAQ, Immunoassay, Security (finance), Nasdaq, Private Securities Litigation Reform Act, Automation, Knowledge, Company, IVD, Â, Nature, EDT, PDT, Quidel Corporation, Terminology, COVID-19, Medical device, Pharmaceutical industry, Online shopping

QuidelOrtho Corporation (NASDAQ: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the third quarter ended October 2, 2022.

Key Points: 
  • QuidelOrtho Corporation (NASDAQ: QDEL) (the Company or QuidelOrtho), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary revenue results for the third quarter ended October 2, 2022.
  • The preliminary revenue results described herein are based on managements initial analysis for the third quarter ended October 2, 2022 and are subject to adjustments based on the Companys completion of its quarter end financial close process.
  • QuidelOrtho will report financial results for its third quarter 2022 after the market close on Wednesday, November 2, 2022.
  • Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss the financial results.

Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

Retrieved on: 
Monday, October 3, 2022
Solution, Hospital, NASDAQ, Adult, Princeton University, Ecosystem, Pharmacy, Bayer, GRF, Legislation, Apollo Global Management, Cerberus Capital Management, AG, Life, Health, Knowledge, Transfusion medicine, CEO, Harvard Law School, LUISS, Chairperson, Goal, MCE, Growth, Coronavirus, Senior, S.A, LLC, Safety, EUR, Sale, Leadership, Plasma, Patient, Acquisition, Retirement, ADR Institute of Alberta, Board, Management, Grifols, Director, Cerberus

It has been an honor to chair the Grifols Board and manage the company for so many years.

Key Points: 
  • It has been an honor to chair the Grifols Board and manage the company for so many years.
  • We know that appointing Steven as Executive Chairperson will facilitate accomplishment of these goals.
  • Grifols' co-CEO's, Victor Grifols Deu and Raimon Grifols Roura, also commented on the appointments.
  • The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.